AZK to lower Crestor price voluntarily

Published: 2008-12-24 06:59:00

Updated: 2008-12-24 06:59:00

The Health Insurance Review and Assessment Service said on December 19 that it has finalized the assessment of economic effectiveness over Crestor, cholesterol-lowering drug to treat the clogging of arteries, following AstraZeneca’s written notice that they would voluntarily reduce Crestor price by 13.2 percent.

AstraZeneca views Crestor as a vital growth driver for the business in the years...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.